Further studies need to focus on certain key immunomodulatory switches, such as CD10330 and CTLA4, in specific IP during the progression from DCIS to IBC, to trace the formation of the IPs and select the more progressive DCIS for early immunotherapy. Here, CTLA4 is linked to ductal breast carcinoma in situ.